Details of the Drug Combination

General Information of Drug Combination (ID: DCHLJ9E)

Drug Combination Name
ABIRATERONE ONAPRISTONE
Indication
Disease Entry Status REF
Prostate Cancer Phase 1 [1]
Component Drugs ABIRATERONE   DM8V75C ONAPRISTONE   DMT6E5N
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of ONAPRISTONE
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [3]
ONAPRISTONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Modulator [5]
------------------------------------------------------------------------------------
ONAPRISTONE Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02049190) Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 Clinical pipeline report, company report or official report of Context Therapeutics.
4 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5 Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8.
6 Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl. 2006 Mar-Apr;27(2):138-50.